- Mission [1]
- FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science
and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities
to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency
preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical
products; establish an effective tabacco regulation, prevention, and control program; and manage for organizational excellence
and accountability. The Transmissible Spongiform Encephalopathies Advisory Committee supports FDA's mission and strategic
action plan by reviewing and evaluating available scientific data concerning the safety of products which may be at risk for
transmission of spongiform encephalopathies having an impact on the public health. The Committee supports FDA's mission by
using science-based efficient risk management in all of its activities. The Committee recommendations provide the most health
promotion and protection at the least cost for the public. This Committee assists the Agency in ensuring timely, high, quality,
cost-effective processes for review of new policies and guidelines, effective communication and working relationships with
stakeholders to enhance U.S. and global health outcomes, accurately analyzing risks associated with medical products, facilitating
the development and availability of medical countermeasures to limit the effects of a terrorist attack on the civilian and
military populations, protecting the safety and security of biologics, including products that may be at risk for transmission
of spongiform encephalopathies, all key components of FDA's strategic plan objectives.
|
